179 related articles for article (PubMed ID: 34295565)
1. Identification of G-protein signaling modulator 2 as a diagnostic and prognostic biomarker of pancreatic adenocarcinoma: an exploration of its regulatory mechanisms.
Zhou X; Dang S; Jiang H; Gu M
J Gastrointest Oncol; 2021 Jun; 12(3):1164-1179. PubMed ID: 34295565
[TBL] [Abstract][Full Text] [Related]
2. Screening and validating the core biomarkers in patients with pancreatic ductal adenocarcinoma.
Li Y; Zhu YY; Dai GP; Wu DJ; Gao ZZ; Zhang L; Fan YH
Math Biosci Eng; 2019 Nov; 17(1):910-927. PubMed ID: 31731384
[TBL] [Abstract][Full Text] [Related]
3. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
Shi T; Gao G
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel candidate biomarkers for pancreatic adenocarcinoma based on TCGA cohort.
Jie Y; Peng W; Li YY
Aging (Albany NY); 2021 Feb; 13(4):5698-5717. PubMed ID: 33591944
[TBL] [Abstract][Full Text] [Related]
5. AMP‑activated protein kinase family member 5 is an independent prognostic indicator of pancreatic adenocarcinoma: A study based on The Cancer Genome Atlas.
Xu H; Mao J; Yang X; Chen F; Song Z; Fei J; Chen W; Zhong Z; Wang X
Mol Med Rep; 2020 Nov; 22(5):4329-4339. PubMed ID: 33000197
[TBL] [Abstract][Full Text] [Related]
6. COL10A1 promotes tumorigenesis by modulating CD276 in pancreatic adenocarcinoma.
Xu Q; Zheng J; Su Z; Chen B; Gu S
BMC Gastroenterol; 2023 Nov; 23(1):397. PubMed ID: 37974070
[TBL] [Abstract][Full Text] [Related]
7.
Kuang W; Wang X; Ding J; Li J; Ji M; Chen W; Wang L; Yang P
Front Immunol; 2022; 13():805311. PubMed ID: 35154122
[TBL] [Abstract][Full Text] [Related]
8. Transmembrane Protein 170B is a Prognostic Biomarker and Associated With Immune Infiltrates in Pancreatic Adenocarcinoma.
Zhang Z; Shang J; Dai Z; Yao Y; Shi Y; Zhong D; Liang Y; Lai C; Yang Q; Feng T; Huang X
Front Genet; 2022; 13():848391. PubMed ID: 35601487
[No Abstract] [Full Text] [Related]
9. A Novel miRNA-mRNA Axis Involves in Regulating Transcriptional Disorders in Pancreatic Adenocarcinoma.
Shang X; Shi LE; Taule D; Zhu ZZ
Cancer Manag Res; 2021; 13():5989-6004. PubMed ID: 34377019
[TBL] [Abstract][Full Text] [Related]
10. Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Network Analysis and Least Absolute Shrinkage and Selection Operator Algorithms.
Yuan Q; Ren J; Wang Z; Ji L; Deng D; Shang D
Front Genet; 2021; 12():692953. PubMed ID: 34490033
[No Abstract] [Full Text] [Related]
11. G-protein-signaling modulator 2 expression and role in a CD133
Dang SC; Qian XB; Jin W; Cui L; Chen JX; Gu M
Onco Targets Ther; 2019; 12():785-794. PubMed ID: 30774366
[TBL] [Abstract][Full Text] [Related]
12. The Prognostic Value and the Oncogenic and Immunological Roles of Vacuolar Protein Sorting Associated Protein 26 A in Pancreatic Adenocarcinoma.
Hou J; Wu H; Xu B; Shang J; Xu X; Li G; Zhang H; Zhang W; Deng Y; Hong X; Hu T; Zhang M; Zhan Y
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834898
[TBL] [Abstract][Full Text] [Related]
13. KRT7 Overexpression is Associated with Poor Prognosis and Immune Cell Infiltration in Patients with Pancreatic Adenocarcinoma.
Li Y; Su Z; Wei B; Liang Z
Int J Gen Med; 2021; 14():2677-2694. PubMed ID: 34188523
[TBL] [Abstract][Full Text] [Related]
14. Construction and Validation of an Immune-Based Prognostic Model for Pancreatic Adenocarcinoma Based on Public Databases.
Mao M; Ling H; Lin Y; Chen Y; Xu B; Zheng R
Front Genet; 2021; 12():702102. PubMed ID: 34335699
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive analysis of G-protein-signaling modulator 2 as a prognostic and diagnostic marker for pan-cancer.
Hu LM; Ou XH; Shi SY
Front Genet; 2022; 13():984714. PubMed ID: 36186420
[No Abstract] [Full Text] [Related]
16. Modeling of new markers for the diagnosis and prognosis of pancreatic cancer based on the transition from inflammation to cancer.
Zhou Y; Huang B; Zhang Q; Yu Y; Xiao J
Transl Cancer Res; 2024 Mar; 13(3):1425-1442. PubMed ID: 38617519
[TBL] [Abstract][Full Text] [Related]
17. The potential drug for treatment in pancreatic adenocarcinoma: a bioinformatical study based on distinct drug databases.
Liu H; Zhou Q; Wei W; Qi B; Zeng F; Bao N; Li Q; Guo F; Xia S
Chin Med; 2020; 15():26. PubMed ID: 32206083
[TBL] [Abstract][Full Text] [Related]
18. PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy.
Du X; Yi X; Zou X; Chen Y; Tai Y; Ren X; He X
BMC Cancer; 2023 Nov; 23(1):1102. PubMed ID: 37957639
[TBL] [Abstract][Full Text] [Related]
19. High Matrix Metalloproteinase 28 Expression is Associated with Poor Prognosis in Pancreatic Adenocarcinoma.
Liu N; Zhong L; Ni G; Lin J; Xie L; Li T; Dan H; Chen Q
Onco Targets Ther; 2021; 14():4391-4406. PubMed ID: 34408436
[TBL] [Abstract][Full Text] [Related]
20. CTSK and PLAU as Prognostic Biomarker and Related to Immune Infiltration in Pancreatic Cancer: Evidence from Bioinformatics Analysis and qPCR.
Ding Y; Li Z; Wang H; Wang Q; Jiang H; Yu Z; Xu M
Int J Genomics; 2023; 2023():3914687. PubMed ID: 38077303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
